Horizon Pharma is going hostile with an all-stock offer for Depomed valued at about $2.1 billion, taking the bid directly to shareholders.
The Dublin-based company says it will offer $29.25 of its stock for each Depomed share. The tax-free offer represents about a 42 percent premium to Depomed's closing price Monday.
Continue Reading Below
Horizon says it has been trying to discuss a deal with Depomed Inc. since March, but that company's board has rejected its proposal. The combined company would have 13 marketed drugs, which would nearly double Horizon's current lineup.
Horizon Pharma Plc has completed four deals in the past two years. They include the acquisitions of Hyperion Therapeutics and the U.S. rights to the rheumatoid arthritis treatment Vimovo.
Shares of Horizon are climbing in premarket trading.